SecBot SecBot
SC 13G/A ·Filed Nov 6, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed10d 15h ago SEC0001897612-26-000704
Passive stake amendment
Actionable Insight • Neutral

Monitor for any further stake changes or conversion to a 13D filing, though T. Rowe Price's passive certification makes activist intent unlikely. The increase is consistent with normal portfolio rebalancing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$39.17
T+0 close · Nov 6, 2026 · via day close
Latest settled
+3.34%
T+5 · $40.48
Vs SPY
+0.75%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $39.17entry
  2. T+1 · 8d ago +3.27%α +0.90% · $40.45
  3. T+5 · 4d ago +3.34%α +0.75% · $40.48
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

T. Rowe Price Investment Management filed an amended Schedule 13G reporting a 10.3% passive stake in Xenon Pharmaceuticals as of October 31, 2026, up from 8.2% as of September 30, 2026. The increase of approximately 2.1 percentage points (about 2 million shares) is a routine passive institutional adjustment with no directional signal.

Key Financial Metrics

Stake
10.3%
Investor
T. Rowe Price Investment Management, Inc.
Investor Type
mutual fund

Key Facts

  • T. Rowe Price Investment Management reported beneficial ownership of 9,996,124 shares of Xenon Pharmaceuticals common stock as of October 31, 2026
  • Stake represents 10.3% of outstanding shares, up from 8.2% (7,905,757 shares) as of September 30, 2026
  • The filing is a routine quarterly update by a passive institutional investor under Rule 13d-1(b)
  • The investor certifies shares were acquired and held in the ordinary course of business, not to influence control

Financial Impact

Increase of approximately 2.09 million shares, valued at roughly $80M based on $3.8B market cap and 10.3% stake

ownership percentage

Risk Factors

  • No material risks identified from this passive stake amendment

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001897612-26-000704
Document: 0001897612-26-000704-index.html0001897612-26-000704
Document: 0001897612-26-000704.txt0001897612-26-000704

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Viewing Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 7h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026